Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Acacia Pharma will sell ByFavo (remimazolam) in the US after a deal with Cosmo (Paion’s Switzerland-based US partner). Cosmo estimates 24.5m endoscopy procedures per year. Acacia may launch its first US product, BARHEMSYS, from mid-2020 but has limited US infrastructure and, as yet, no salesforce. We are updating our Paion valuation (formerly €317m).
Written by
Paion |
Acacia to sell ByFavo in US |
US sales channel |
Pharma and biotech |
14 January 2020 |
Share price performance
Business description
Analyst
Paion is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||
Acacia Pharma will sell ByFavo (remimazolam) in the US after a deal with Cosmo (Paion’s Switzerland-based US partner). Cosmo estimates 24.5m endoscopy procedures per year. Acacia may launch its first US product, BARHEMSYS, from mid-2020 but has limited US infrastructure and, as yet, no salesforce. We are updating our Paion valuation (formerly €317m).
Year end |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
5.8 |
(15.9) |
(20.5) |
0.0 |
N/A |
N/A |
12/18 |
2.8 |
(12.4) |
(15.9) |
0.0 |
N/A |
N/A |
12/19e |
8.0 |
(11.1) |
(14.2) |
0.0 |
N/A |
N/A |
12/20e |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
The FDA’s review of ByFavo will complete by 5 April 2020 (PDUFA) with, if favourable, a possible launch event at ANESTHESIOLOGY 2020 on 3–7 October. Cosmo now works with partner marketing companies in which it takes strategic stakes. Acacia will pay, though Cosmo, an estimated 20% royalty to Paion on final sales. Acacia’s lead product, BARHEMSYS, could be approved by 26 February 2020. Cosmo’s cash will enable Acacia to set up a US sales operation. Key managers may start from summer 2020 with a salesforce of up to 60+ planned.
BARHEMSYS (a rescue therapy for nausea and vomiting) will be used by inpatient hospital recovery rooms and intensive care units. In contrast, in the US ByFavo is an outpatient procedural sedative targeted at midazolam (which does not need an anaesthetist) for use in endoscopy suites or ambulatory surgery clinics, of which many are private. Hence, direct sales synergies may be limited but having two products will give Acacia better salesforce economics. Cosmo estimates the ByFavo market at 24.5m procedures per year. Assuming 90% midazolam use and 80% market coverage, this is a 17.6m dose potential market. ByFavo will cost more than generic midazolam but with higher throughput to offset the extra cost. Paion has completed a deal in Asia with Hana Pharm (€1.5m) and may also gain 2020 milestones, assuming approvals in the US and Japan, estimated by us at up to €20m. Paion is transitioning into a commercial company so we have suspended our forecast and valuation whilst we update our model and expectations.
|
|
Research: TMT
The breadth of IQE’s technology portfolio and ability to serve compound semiconductor chip customers in the US and Asia puts it in a good position to benefit from rising demand for compound semiconductor applications for 5G and connected devices. The share price has been hit by the shift to Asian-centric supply chains caused by US-Chinese trade tensions, and resultant reductions to management guidance. Although the timing of a recovery is difficult to gauge, we see scope for earnings recovery as IQE secures additional contracts in Asia and leverages its IP portfolio into sustainable profit growth and cash generation.